These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 20926399

  • 1. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 2. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.
    Hum Gene Ther; 2011 Dec 15; 22(12):1575-86. PubMed ID: 21838572
    [Abstract] [Full Text] [Related]

  • 3. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 4. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 5. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ.
    Oncotarget; 2015 Oct 06; 6(30):28911-28. PubMed ID: 26359629
    [Abstract] [Full Text] [Related]

  • 6. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.
    Cancer Immunol Res; 2013 Jul 06; 1(1):26-31. PubMed ID: 24777247
    [Abstract] [Full Text] [Related]

  • 7. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.
    Proc Natl Acad Sci U S A; 2016 Jan 26; 113(4):E450-8. PubMed ID: 26759368
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19+ Tumor Cells.
    Lin Z, Liu X, Liu T, Gao H, Wang S, Zhu X, Rong L, Cheng J, Cai Z, Xu F, Tan X, Lv L, Li Z, Sun Y, Qian Q.
    Front Immunol; 2021 Jan 26; 12():802705. PubMed ID: 35082789
    [Abstract] [Full Text] [Related]

  • 9. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 10. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb 01; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 11. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, Li B, Pan H, Jiang Z, Shen X, Liang Z, Liang Y, Zhu H.
    Front Immunol; 2021 Feb 01; 12():628906. PubMed ID: 33777013
    [Abstract] [Full Text] [Related]

  • 12. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 01; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
    Foster JB, Choudhari N, Perazzelli J, Storm J, Hofmann TJ, Jain P, Storm PB, Pardi N, Weissman D, Waanders AJ, Grupp SA, Karikó K, Resnick AC, Barrett DM.
    Hum Gene Ther; 2019 Feb 01; 30(2):168-178. PubMed ID: 30024272
    [Abstract] [Full Text] [Related]

  • 15. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
    Clin Cancer Res; 2013 Apr 15; 19(8):2048-60. PubMed ID: 23344265
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF, Turazzi N, Benedicenti F, Calabria A, Tenderini E, Tettamanti S, Giordano Attianese GM, Cooper LJ, Aiuti A, Montini E, Biondi A, Biagi E.
    Oncotarget; 2016 Aug 09; 7(32):51581-51597. PubMed ID: 27323395
    [Abstract] [Full Text] [Related]

  • 17. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.
    Hum Gene Ther; 2018 May 09; 29(5):614-625. PubMed ID: 29334771
    [Abstract] [Full Text] [Related]

  • 18. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, Fan R.
    J Immunother Cancer; 2021 May 09; 9(5):. PubMed ID: 34006631
    [Abstract] [Full Text] [Related]

  • 19. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.
    J Immunother Cancer; 2017 May 09; 5():42. PubMed ID: 28515942
    [Abstract] [Full Text] [Related]

  • 20. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ.
    PLoS One; 2013 May 09; 8(5):e64138. PubMed ID: 23741305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.